Company Filing History:
Years Active: 2016-2022
Title: Willem Dokter: A Pioneering Inventor in Antitumor Therapy
Introduction
Willem Dokter, an innovative inventor based in Nijmegen, Netherlands, has made significant contributions to the field of biopharmaceuticals. With a portfolio that includes three patents, he is known for his groundbreaking work on antibody-drug conjugates (ADCs), specifically targeting improved treatment methods for various cancers.
Latest Patents
One of Dokter's latest patents involves duocarmycin-containing ADCs that demonstrate enhanced in vivo antitumor activities. This invention focuses on the treatment of human solid tumours and hematological malignancies expressing HER2, especially for types such as breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer, osteosarcoma, and acute lymphoblastic leukaemia. Notably, his research is directed towards treating triple-negative breast cancer (TNBC) and solid tumours characterized by HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status.
Career Highlights
Willem Dokter has collaborated with leading companies in the biopharmaceutical sector, including Synthon Biopharmaceuticals B.V. and Byondis B.V. His work at these organizations has played a crucial role in advancing cancer treatments through innovative drug delivery systems.
Collaborations
Throughout his career, Dokter has had the opportunity to work alongside talented professionals including Peter Johannes Goedings and Gijsbertus Franciscus Maria Verheijden. These collaborations have enriched his research and enhanced the development of his patents.
Conclusion
Willem Dokter's contributions to the field of cancer therapy, particularly through his innovations in duocarmycin-containing ADCs, underscore his status as a leading figure in biopharmaceutical research. His dedication to improving treatment modalities for various cancers continues to have a significant impact on patients and the medical community alike.